Lv1
46 积分 2022-10-26 加入
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
1个月前
已完结
Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
1个月前
已完结
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
1个月前
已完结
Effects of different B-cell-depleting strategies on the lymphatic tissue
1个月前
已完结
Parallel improvement of chorea and antiphospholipid autoimmunity during combination therapy with hydroxychloroquine, belimumab, and glucocorticoids in systemic lupus erythematosus
1个月前
已完结
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus
1个月前
已完结
Refractory antiphospholipid antibody syndrome–induced thrombocytopaenia successfully treated with belimumab
1个月前
已完结
Belimumab reduces antiphospholipid antibodies in primary triple-positive antiphospholipid syndrome
1个月前
已完结
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
1个月前
已完结
Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment
1个月前
已完结
皖公网安备34019202002308
